WITTEN, Germany--(BUSINESS WIRE)--Together with Excellence Cluster Cardio-Pulmonary System (ECCPS) and TransMIT Gesellschaft für Technologietransfer mbH (TransMIT), Sangui is investigating new therapeutic approaches to treating septic shock and acute respiratory distress syndrome (ARDS).
Owing to their incidence rate, complexity and poor prognosis, the two diseases constitute a huge challenge in both in terms of their socio-economic impact and the associated intensive medical care, and incur unacceptably high mortality rates, despite progress made in intensive medicine. In Germany alone, 150,000 people a year are afflicted by sepsis, and the mortality rate is 30–50% even with maximum therapy. Targeted antibiotic therapy, artificial respiration, preserving the functions of organs, and supporting circulation through liquid infusions and hypertension-inducing drugs form part of an optimised therapy. The infusions of vasoconstrictive substances, such as adrenaline or noradrenaline, are intended to normalise dangerously low blood pressure. Raising the global blood pressure (macrocirculation) is, however, detrimental to the closing of small vessels (microcirculation) whose main task is peripheral oxygen delivery. This lack of oxygen poses a huge problem for many organs, such as the kidneys or intestines.
The approach adopted here by Sangui, ECCPS and TransMIT presupposes that self-perpetuating septic shock, that has so far been highly resistant to treatment, can be interrupted by Sangui's artificial haemoglobin-based oxygen carrier, which would ultimately lower mortality rates. The preclinical trials at ECCPS which are now approved aim to investigate the effect of various haemoglobin preparations on the oxygen supply of a number of organs in septic shock and ARDS models. The research alliance has devised a plan which uses a preparation similar to Granulox provided by Sangui and will work towards certification as a Class III medical device if the approach proves its worth and is successful.
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB marketplace (www.otcmarkets.com: SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges. Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.
Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.